RT @DrPetryna: #eular2020 #op0226 humanized antiIL17a ab NETAKIMAB (NTK)for PsA Ph3 PATERA trial: pts who failed cDMARDs

Social Author Image
https://pbs.twimg.com/profile_images/1010360126954491904/BUlKU6N_.jpg
Tweet Author
DrPetryna
Social Author Name
Olga Petryna
Tweet Content
#eular2020 #op0226 humanized antiIL17a ab NETAKIMAB (NTK)for PsA Ph3 PATERA trial: pts who failed cDMARDs and/or 1TNFi experience significantly ⬆️ ACR20/50/70 &PsACR response vs PBO. DAPSA remission 36.08% NTK vs 13.4%PBO. AEs: lympho&neutropenia, ⬆️cholesterol,⬆️bili @RheumNow https://t.co/xqc9Z1T9O0
Show on Archive Page
On
Display in Search Results
On

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×